Health Tech

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Today (Nov 7, 2025): ORCL Slips on Oracle‑Linked Cyber Breach Headlines as New Health‑AI Partnership Lands

Updated: November 7, 2025 Oracle (NYSE: ORCL) shares were lower in midday trading on Friday after fresh headlines tied a high‑profile cyber breach to Oracle software, partially offsetting a same‑day announcement of a new oncology data and AI collaboration. As of early afternoon, ORCL was trading around the mid‑$230s, down roughly 3% from Thursday’s close, with an intraday range in the low‑$230s to high‑$230s. Reuters’ live quote page showed shares recently at $236.21 (-3.11%), versus a prior close of $243.80 and an intraday range of $232.36–$239.42. Reuters What moved Oracle stock today Cyber breach headlines: The Washington Post said it

7 November 2025

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for hospital-grade remote monitoring, enabling cuffless measurement of blood pressure, heart rate, SpO2, and respiratory rate via PPG and AI. On June 19, PharmaSens and SiBionics announced niia™ signature, an all-in-one patch that combines a continuous glucose monitor with an insulin pump, unveiled at ADA 2025. LifePlus’s LifeLeaf non-invasive monitor (June 24) is a cuffless device for continuous glucose and blood pressure tracking, validated in Mayo Clinic trials with readings within about 10.8% of glucometers and BP error around 0.03 mmHg. Wearable Devices Ltd.’s Large-Motion AI Platform expansion on June

7 July 2025

Digital Health · Health Tech · Industry News · NASDAQ:AAPL · NASDAQ:DXCM · NYSE:ABT · Technology · Wearables

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3

27 June 2025

2025 Trends · Biotechnology · Forecast · Health Tech · Medical Innovation · NASDAQ:ABEO · NASDAQ:ITCI · NASDAQ:PRME · NASDAQ:RARE · NASDAQ:RGLS · NASDAQ:SWTX · NASDAQ:VRTX · NASDAQ:WVE · NYSE:AZN · NYSE:CTLT · NYSE:JNJ · NYSE:NVO · NYSE:NVS

Trends 2025: Consumer Electronics & Wearables – AI, AR, Health Tech and More (Updated: June 27th, 2025)

Global consumer tech sales are projected to reach $1.29 trillion in 2025, about 2% growth over 2024. Apple leads wearables with roughly a 20–25% global market share in recent quarters, driven by its Watch and AirPods lines. Wearable shipments grew 5.4% in 2024 to 534.6 million units and are expected to grow 4.1% in 2025 as key segments mature. IDC projects wearables unit shipments around 560 million in 2025, with hearables and smartwatches remaining the largest categories by volume. At CES 2025, Halliday unveiled smart glasses with an invisible DigiWindow heads-up display and built-in AI assistant, slated for release by

27 June 2025

2025 Trends · Artificial Intelligence · Consumer Electronics · Health Tech · Wearables